Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02811211 · ClinicalTrials.gov registry record
A Noninterventional Genotype/Phenotype Study of mGluR Mutations in Children and Adolescents With ADHD
A clinical trial, sponsored by Aevi Genomic Medicine, LLC, a Cerecor company.
- Completed
- Registry status
- 1,894
- Enrollment target
NCT02811211: Completed study, sponsored by Aevi Genomic Medicine, LLC, a Cerecor company.
NCT02811211 is a clinical trial that has completed, run by Aevi Genomic Medicine, LLC, a Cerecor company. The registered enrollment target is 1,894 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02811211 has completed, sponsored by Aevi Genomic Medicine, LLC, a Cerecor company.
- COMPLETED
- Registry status
- 1,894 participants
- Enrollment target
Study Summary
This noninterventional study will assess genomic changes in the metabotropic glutamate receptor (mGluR) network in children and adolescents with ADHD.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,894 participants |
| Start Date | 2016-02 |
| Est. Completion | 2017-01-06 |
What the finished NCT02811211 record still lists
NCT02811211 is an observational study that tracks outcomes without assigning an intervention. Its 1,894 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT02811211 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02811211 about?
NCT02811211 is a clinical study titled "A Noninterventional Genotype/Phenotype Study of mGluR Mutations in Children and Adolescents With ADHD". This noninterventional study will assess genomic changes in the metabotropic glutamate receptor (mGluR) network in children and adolescents with ADHD.
What is the current status of trial NCT02811211?
This trial is currently completed. The enrollment target is 1,894 participants. The study started on 2016-02. Estimated completion is 2017-01-06.
Who is sponsoring clinical trial NCT02811211?
This trial is sponsored by Aevi Genomic Medicine, LLC, a Cerecor company, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07308717 · 1,896 participants · Phase 4
Gabapentin And Breast Surgery Decision Architecture Randomization Trial (GABS-DART) Protocol
- NCT03729180 · 1,900 participants · NA
The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery
- NCT05712200 · 1,900 participants · Phase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
- NCT06929806 · 1,900 participants · Phase 3
Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia